Vyant Bio (OTCMKTS:VYNT) Shares Up 7.8%

Vyant Bio, Inc. (OTCMKTS:VYNT) shares shot up 7.8% during trading on Thursday . The company traded as high as $0.20 and last traded at $0.19. 19,100 shares were traded during trading, a decline of 88% from the average session volume of 161,822 shares. The stock had previously closed at $0.18.

Vyant Bio Trading Up 7.8 %

The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.86 and a current ratio of 2.86. The business has a 50 day moving average of $0.19 and a 200 day moving average of $0.18.

Institutional Trading of Vyant Bio

An institutional investor recently raised its position in Vyant Bio stock. Captrust Financial Advisors raised its position in Vyant Bio, Inc. (OTCMKTS:VYNT) by 405,350.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 202,725 shares of the company’s stock after purchasing an additional 202,675 shares during the quarter. Captrust Financial Advisors owned 3.45% of Vyant Bio worth $113,000 at the end of the most recent quarter.

Vyant Bio Company Profile

Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).